Pneumococcal 20-Valent Conjugate Vaccine Dosage

Medically reviewed by Drugs.com. Last updated on Feb 23, 2024.

Usual Adult Dose for Pneumococcal Disease Prophylaxis

0.5 mL IM once as a single dose

Comments:

• Use for the prevention of pneumonia caused by Streptococcus pneumoniae serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity assay. Continued approval may depend on verification and description of clinical benefit in a confirmatory trial.

Use: For active immunization for the prevention of pneumonia caused by S pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F

Usual Pediatric Dose for Pneumococcal Disease Prophylaxis

Vaccination Schedule for Patients 6 Weeks Through 15 Months of Age: 0.5 mL IM for 4 doses, given at 2, 4, 6, and 12 through 15 months of age

Catch-Up Vaccination Schedule for Unvaccinated Patients 7 Months through 17 Years of Age:

• Age 7 through 11 months at first dose: 0.5 mL IM for 3 doses
• The first 2 doses: Given at least 4 weeks apart
• The third dose: Given after the first birthday and at least 2 months after the second dose
• Age 12 through 23 months at first dose: 0.5 mL IM for 2 doses, given at least 2 months apart
• Age 24 months and older at first dose: 0.5 mL IM once

Catch-Up Vaccination Schedule for Patients Previously Vaccinated With At Least 1 Dose of a Lower Valency Pneumococcal Conjugate Vaccine:

• Age 15 months through 17 years: 0.5 mL IM once, at least 8 weeks after the last dose of the lower valency vaccine

Comments:

• First dose may be given as early as 6 weeks of age.
• There should be at least 2 months between the 3rd and 4th dose.

Uses:

• For active immunization for the prevention of invasive disease caused by S pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks and older
• For active immunization for the prevention of otitis media caused by S pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F in individuals 6 weeks through 5 years of age

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

• Severe allergic reaction (e.g., anaphylaxis) to any of the ingredients or to diphtheria toxoid

Safety and efficacy have not been established in patients younger than 6 weeks.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• For IM use only
• Inform the patient of potential benefits and risks prior to administration.
• Administer the vaccine as soon as it is removed from the refrigerator.
• Can be administered provided total time out of refrigeration (at 8C to 25C) does not exceed 96 hours; cumulative multiple excursions between 0C and 2C are permitted if the total time does not exceed 72 hours.
• Do not mix with other vaccines/products in the same syringe.

Storage requirements:

• Store horizontally (to minimize resuspension time) in the refrigerator between 2C and 8C (36F and 46F).
• Do not freeze. Discard if the vaccine is frozen.

Reconstitution/preparation techniques:

• The manufacturer product information should be consulted.

General:

• Suspected adverse reactions should be reported by contacting the Vaccine Adverse Event Reporting System (VAERS) at https://vaers.hhs.gov.

Patient advice:

• Report possible adverse reactions to your health care provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer